These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 17082236

  • 1. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.
    Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T.
    J Am Soc Nephrol; 2006 Dec; 17(12):3438-46. PubMed ID: 17082236
    [Abstract] [Full Text] [Related]

  • 2. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
    Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T.
    Hypertension; 2007 Nov; 50(5):877-83. PubMed ID: 17875821
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M, Fujita T.
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [Abstract] [Full Text] [Related]

  • 5. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, Noma T, Kohno M, Nishiyama A, Nakano D.
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.
    Nagase M.
    Clin Exp Nephrol; 2010 Aug; 14(4):303-14. PubMed ID: 20533072
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome.
    Shibata S, Fujita T.
    Mol Cell Endocrinol; 2012 Mar 24; 350(2):273-80. PubMed ID: 21820485
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
    Fukuda A, Fujimoto S, Iwatsubo S, Kawachi H, Kitamura K.
    Nephrology (Carlton); 2010 Apr 24; 15(3):321-6. PubMed ID: 20470301
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
    Matsui H, Ando K, Kawarazaki H, Nagae A, Fujita M, Shimosawa T, Nagase M, Fujita T.
    Hypertension; 2008 Aug 24; 52(2):287-94. PubMed ID: 18606904
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D, Tanabe A, Naruse M, Morikawa S, Ezaki T, Takano K.
    Hypertens Res; 2009 Sep 24; 32(9):807-15. PubMed ID: 19662019
    [Abstract] [Full Text] [Related]

  • 16. Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system.
    Nagase M, Fujita T.
    Curr Diabetes Rev; 2011 Jan 24; 7(1):8-16. PubMed ID: 21067506
    [Abstract] [Full Text] [Related]

  • 17. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats.
    Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, Shibata H, Nagai Y, Mori H, Masaki T, Kobori H, Nishiyama A.
    PLoS One; 2012 Jan 24; 7(7):e41896. PubMed ID: 22911865
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
    Hosoya K, Minakuchi H, Wakino S, Fujimura K, Hasegawa K, Komatsu M, Yoshifuji A, Futatsugi K, Shinozuka K, Washida N, Kanda T, Tokuyama H, Hayashi K, Itoh H.
    Kidney Int; 2015 Apr 24; 87(4):749-60. PubMed ID: 25337775
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.